SUMMARY
Chlordiazepoxide Hydrochloride Capsules USP C-IV
Rx only
Chlordiazepoxide hydrochloride is the prototype for the benzodiazepine compounds. Chlordiazepoxide hydrochloride is 7-chloro-2-(methylamino)-5-phenyl-3 H -1,4-benzodiazepine 4-oxide hydrochloride. A white to practically white crystalline substance, it is soluble in water. It is unstable in solution and the powder must be protected from light.
Chlordiazepoxide HCI Capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.
The effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.
|
NEWS HIGHLIGHTS
Published Studies Related to Chlordiazepoxide
A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal. [2009.05]
CONCLUSIONS: With the treatment schedule used in this study, lorazepam is as effective as the more traditional drug chlordiazepoxide in attenuating uncomplicated alcohol withdrawal. Lorazepam, therefore, could be used with confidence when liver disease or the inability to determine liver function status renders chlordiazepoxide therapy problematic. The absence of clinically significant withdrawal complications with lorazepam in this large study contrasts with findings from previously published studies and suggests that higher doses of lorazepam than those formerly used may be necessary during alcohol withdrawal.
A double-blind randomized placebo-controlled trial of lofexidine in alcohol withdrawal: lofexidine is not a useful adjunct to chlordiazepoxide. [2001.09]
Lofexidine is an alpha-adrenoceptor agonist which has proved useful in opiate withdrawal and which, through its attenuation of noradrenergic activity, might be a valuable adjunct in the management of alcohol withdrawal. The objective of this study was to compare the clinical effectiveness and patient retention with adjunctive lofexidine versus placebo in the treatment of alcohol withdrawal under chlordiazepoxide cover...
The comparison of the effects of multi and single doses of buspirone, chlordiazepoxide and hydroxyzine on psychomotor function and EEG. [1992]
This study compares the effects of buspirone (5 mg), chlordiazepoxide (5 mg), hydroxyzine (10 mg) and placebo on psychomotor function and EEG, when taken thrice daily for a period of two weeks, with those after a single dose administration... Spectral analysis of the EEG did not distinguish between the multi and single dosage schedules regarding the respective drugs in the low doses administered.
Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial. [1991.03]
In a prospective, double-blind comparison, we assessed the efficacy of transdermal clonidine with that of chlordiazepoxide in the treatment of moderately severe acute alcohol withdrawal syndrome. While having significant withdrawal symptoms, 50 hospitalized men were randomly assigned to receive either transdermal clonidine or chlordiazepoxide over a 4-day study period.
Chlordiazepoxide vs. methadone in opiate withdrawal: a preliminary double blind trial. [1989.01]
A double blind trial of chlordiazepoxide vs. methadone in the management of the opiate withdrawal syndrome was conducted in a group of 24 regular heroin takers...
Clinical Trials Related to Chlordiazepoxide
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation [Completed]
This study aims mainly to investigate the effects of two approaches to control blood pressure
in hypertensive hemodialysis patients; using antihypertensive drugs versus strict volume
control (by strict dietary salt restriction and persistent ultrafiltration) without using
antihypertensive drugs on cardiac structure and inflammation.
Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data [Completed]
The majority of asthma patients are not well controlled, despite the availability of asthma
medication that could effectively treat the disease. In this study uncontrolled patients who
are steroid-naive or on low dose inhaled corticosteroids will be treated with
Salmeterol/Fluticasone combination (SFC) 50/250 µg bd. The asthma control test (ACT) will be
used to detect differences in the level of asthma control during treatment. The study aims to
show a correlation between improvements of ACT und the level of asthma control which will be
reached by the patients.
The aim of the study is to show that most of symptomatic asthma patients can reach 'well
controlled asthma' with SFC. We get information about ACT in daily practice and physicians
are trained to use the asthma control test as a screening tool and for follow up of asthma
management. Correlations are expected between the improvements in ACT, Quality of Life and
asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.
Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study [Recruiting]
In a prospective and randomized study protocol, three different blood pressure regulating
agents (nitroprusside, nitroglycerine, sevoflurane) will be compared concerning their effect
on the cerebral oxygen balance between both hemispheres during aortic coarctation repair.
Cerebral and somatic saturation will be monitored non-invasively and continuously via
optical sensors applied to the right and left forehead and the somatic regions. Arterial
blood pressure, central venous pressure, heart rate and systemic saturation will be recorded
continuously. Intermittently, arterial and venous blood gas analysis will be performed at 6
definite time intervals. The study ends at the end of the operation.
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes [Recruiting]
This study in Germany is designed to compare the effects of twice-daily exenatide plus
metformin and twice-daily premixed human insulin aspart plus metformin with respect to
glycemic control, as measured by HbA1c, combined with the percentage of patients with at
least one treatment-emergent hypoglycemic episode. Patients will be treated with study
therapy for approximately 26 weeks.
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
Ninety percent of patients with type-1-diabetes will develop late-diabetic complications in
the eyes, kidneys, nervous- or cardiovascular-system. Poor glycaemic control is an important
risk-factor for development of these late-diabetic complications. The Diabetes Control and
Complications Trial (DCCT)-study showed, that improved glycaemic control can prevent the
development and progression of these late-diabetic complications. Until now treatment with
insulin- and diet-therapy has been the only treatment-modalities available to improve the
glycaemic control in patients with type-1-diabetes. A substantial number of these patients
still have long-standing poor glycaemic control despite intensive treatment with insulin- and
diet-therapy.
The antidiabetic drug metformin has shown to be able to improve the glycaemic control in
combination with insulin and furthermore reduce both mortality and the risk of developing
cardiovascular disease in patients with type-2-diabetes.
Only few small studies have investigated the effect of treatment with metformin in patients
with type-1-diabetes. These studies have suggested a positive effect of metformin in these
patients too.
Method:
100 patients with type-1-diabetes with persistent poor glycaemic control i. e. HbA1c > 8. 5%
during the last 12 months are eligible. Patients are treated for one month with placebo.
Hereafter half of the patients will be treated with metformin and the other half continues
with placebo for 12 months both as add-on therapy. All patients are continuing ongoing
treatment with insulin throughout the study. Before and after the start of treatment with
metformin the effect on glycaemic control and other known risk-factors for development of
cardiovascular disease i. e. blood-pressure, fasting lipids, urine-albumine-excretion,
endothelial dysfunction, inflammation, fibrinolysis etc. is assessed.
This study will show if treatment with metformin can improve the glycaemic control and hereby
the prognosis of patients with type-1-diabetes with persistent poor glycaemic control despite
intensive treatment with insulin- and diet-therapy. This group of patients suffers the
highest risk of developing late-diabetic complications with reduced quality of life and
life-expectancy as a consequence.
|
